
PATENT COOPERATION TREAT

PCT

INTERNATIONAL PRELIMINARY EXAMINATION REPORT


tio	PATENT CO	OOPERATION TREA	I (BAIMA BANKA) (M BAIMA (MYS) MYA BITTA) FI
nslav		PCT	10/5357
anslation	INTERNATIONAL PRE	LIMINARY EXAMINA	ATION REPORT
		Article 36 and Rule 70)	
Applicant's or agent's fil -PH-1902	I KORKUKU	HER ACTION See Notific Preliminary	eation of Transmittal of Internati Examination Report (Form PCT/IPEA/4
International application	`	iling date (day/month/year) ber 2003 (20.11.2003)	Priority date (day/month/year) 21 November 2002 (21.11.20
PCT/JP2003	sification (IPC) or national classific	ation and IPC	l
C12N 15/54, 9	9/10, C07K 16/40, C12N 1/15, 1/	/19, 1/21, 5/10, C12Q 1/48,	A61K 38/45, A61P 35/00
Anntionnt			
Applicant	CHUGAI SEIYA	AKU KABUSHIKI KAIS	SHA
70.16 an	and Section 607 of the Administrative nexes consist of a total of	Instructions under the PCT) sheets.	ations made before this Authority (see
п	Certain documents cited	35(2) with regard to novelty, ing such statement	
	Lack of unity of invention Reasoned statement under Article citations and explanations supporti Certain documents cited Certain defects in the international	35(2) with regard to novelty, in such statement application	
III	Lack of unity of invention Reasoned statement under Article citations and explanations supporti Certain documents cited	35(2) with regard to novelty, in such statement application	
	Lack of unity of invention Reasoned statement under Article: citations and explanations supporti Certain documents cited Certain defects in the international Certain observations on the interna	35(2) with regard to novelty, in such statement application	nventive step or industrial applicability;
III	Lack of unity of invention Reasoned statement under Article: citations and explanations supporti Certain documents cited Certain defects in the international Certain observations on the interna	35(2) with regard to novelty, in such statement application application. Date of completion	nventive step or industrial applicability;
III	Lack of unity of invention Reasoned statement under Article citations and explanations supporti Certain documents cited Certain defects in the international Certain observations on the international the demand rember 2003 (20.11.2003)	35(2) with regard to novelty, in such statement application application. Date of completion	nventive step or industrial applicability;

INTERNATIONAL PRELIMINARY EXAMINATION REPORT



L	Basis (of the rep	ort		
1.	With	regard to	the elements of the international application:*		
	\boxtimes	the interr	national application as originally filed		
	币	the descr	ription:		
		pages	, as originally filed		
		pages	, filed with the demand		
		pages	, filed with the letter of		
	_	_			
	Ш	the claim			
		pages _	, as originally filed		
		pages _	, as amended (together with any statement under Article 19		
		pages _	, filed with the demand		
	_	pages _	, filed with the letter of		
	Ш	the draw	•		
		pages _	, as originally filed		
		pages _	, filed with the demand		
		pages _	, filed with the letter of		
		the sequen	nce listing part of the description:		
		pages	, as originally filed		
		pages	, filed with the demand		
		pages _	, filed with the letter of		
2.	the ir	nternations e elements	the language, all the elements marked above were available or furnished to this Authority in the language in which al application was filed, unless otherwise indicated under this item. s were available or furnished to this Authority in the following language which is: guage of a translation furnished for the purposes of international search (under Rule 23.1(b)).		
	\sqcap	_	guage of publication of the international application (under Rule 48.3(b)).		
		_	guage of the translation furnished for the purposes of international preliminary examination (under Rule 55.2 and/		
3.	With	n regard i minary ex	to any nucleotide and/or amino acid sequence disclosed in the international application, the international amination was carried out on the basis of the sequence listing:		
l		containe	ed in the international application in written form.		
		filed together with the international application in computer readable form. furnished subsequently to this Authority in written form.			
	furnished subsequently to this Authority in computer readable form.				
			atement that the subsequently furnished written sequence listing does not go beyond the disclosure in the ional application as filed has been furnished.		
		The state	tement that the information recorded in computer readable form is identical to the written sequence listing has mished.		
4.		The am	endments have resulted in the cancellation of:		
			the description, pages		
			the claims, Nos		
			the drawings, sheets/fig		
5.		This rep	ort has been established as if (some of) the amendments had not been made, since they have been considered to go the disclosure as filed, as indicated in the Supplemental Box (Rule 70.2(c)).**		
•	in th	acement s nis report 70.17).	heets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to as "originally filed" and are not annexed to this report since they do not contain amendments (Rule 70.16		
**	'Any i	replaceme	ent sheet containing such amendments must be referred to under item 1 and annexed to this report.		





V. Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement						
tatement						
Novelty (N)	Claims	11-17	YES			
	Claims	1-10, 18-20	NO			
Inventive step (IS)	Claims		YES			
	Claims	1-20	МО			
Industrial applicability (IA)	Claims	1-20	YES			
	Claims		NO			

2. Citations and explanations

Document 1: WO, 02-46426, A2

Document 1 discloses DME8, one of drug-metabolizing enzymes cloned from a human, of which the amino acid sequence is represented by SEQ ID NO.: 8 and the base sequence is represented by SEQ ID NO.: 21. It also describes that DME8 is highly homologous with N acetylglucosamine transferase of human origin. In the claims, a gene encoding DME8, a vector, recombinant cells, an antibody to DME8, a probe for detecting polynucleotide hybridizing a DME8 gene, and the like are mentioned.

The amino acid sequence of DME8 shown in document 1 has an about 86% identity with the SEQ ID NO.: 2 of the invention of the present application (by the use of the alignment parameters shown in the description of the present application), and the base sequence of DME8 has an about 96% identity with the SEQ ID NO.: 1 (the portion corresponding to ORF) of the invention of the present application.

Thus, the subject matters of claims 1-10 and 18-20 of the present application are the same as the inventions of document 1 and do not appear to be novel.

The involvement of the sugar chain structure in the transmission of signals to cancerous cells was well known to a person skilled in the art before the date of priority of the present application and so a person skilled in the art could have easily arrived at the possibility of using, as an anticancer agent, an antibody to a protein having a high homology with N acetylglucosamine transferase and screening compounds which interact with DME8. Furthermore, the invention of the present application does not produce a greater effect than that expected by a person skilled in the art.

Accordingly, the subject matters of claims 11-17 of the present application could have been easily conceived of by a person skilled in the art on the basis of the invention of document 1 and so do not appear to involve an inventive step.